Bifogade filer
PDF
Kurs
+1,77%
Likviditet
0,73 MSEK
Kalender
| Est. tid* | ||
| 2026-12-03 | N/A | Årsstämma |
| 2026-10-07 | 08:15 | Bokslutskommuniké 2026 |
| 2026-06-24 | 08:15 | Kvartalsrapport 2026-Q3 |
| 2026-04-08 | - | Extra Bolagsstämma 2026 |
| 2026-03-25 | - | Kvartalsrapport 2026-Q2 |
| 2026-01-28 | - | Kvartalsrapport 2026-Q1 |
| 2025-12-05 | - | X-dag ordinarie utdelning DMYD B 0.00 SEK |
| 2025-12-04 | - | Årsstämma |
| 2025-10-08 | - | Bokslutskommuniké 2025 |
| 2025-06-25 | - | Kvartalsrapport 2025-Q3 |
| 2025-05-09 | - | X-dag ordinarie utdelning DMYD B 0.00 SEK |
| 2025-04-09 | - | Kvartalsrapport 2025-Q2 |
| 2025-01-29 | - | Kvartalsrapport 2025-Q1 |
| 2024-12-05 | - | Årsstämma |
| 2024-10-09 | - | Bokslutskommuniké 2024 |
| 2024-06-26 | - | Kvartalsrapport 2024-Q3 |
| 2024-05-08 | - | X-dag ordinarie utdelning DMYD B 0.00 SEK |
| 2024-03-27 | - | Kvartalsrapport 2024-Q2 |
| 2024-01-24 | - | Kvartalsrapport 2024-Q1 |
| 2023-12-01 | - | X-dag ordinarie utdelning DMYD B 0.00 SEK |
| 2023-11-30 | - | Årsstämma |
| 2023-10-11 | - | Bokslutskommuniké 2023 |
| 2023-10-10 | - | Extra Bolagsstämma 2023 |
| 2023-06-28 | - | Kvartalsrapport 2023-Q3 |
| 2023-04-05 | - | Kvartalsrapport 2023-Q2 |
| 2023-01-25 | - | Kvartalsrapport 2023-Q1 |
| 2022-12-02 | - | X-dag ordinarie utdelning DMYD B 0.00 SEK |
| 2022-12-01 | - | Årsstämma |
| 2022-10-05 | - | Bokslutskommuniké 2022 |
| 2022-06-22 | - | Kvartalsrapport 2022-Q3 |
| 2022-03-30 | - | Kvartalsrapport 2022-Q2 |
| 2022-01-26 | - | Kvartalsrapport 2022-Q1 |
| 2021-12-03 | - | X-dag ordinarie utdelning DMYD B 0.00 SEK |
| 2021-12-02 | - | Årsstämma |
| 2021-10-13 | - | Bokslutskommuniké 2021 |
| 2021-06-23 | - | Kvartalsrapport 2021-Q3 |
| 2021-03-25 | - | Kvartalsrapport 2021-Q2 |
| 2021-01-20 | - | Kvartalsrapport 2021-Q1 |
| 2020-11-27 | - | X-dag ordinarie utdelning DMYD B 0.00 SEK |
| 2020-11-26 | - | Årsstämma |
| 2020-10-07 | - | Bokslutskommuniké 2020 |
| 2020-06-24 | - | Kvartalsrapport 2020-Q3 |
| 2020-03-25 | - | Kvartalsrapport 2020-Q2 |
| 2020-01-22 | - | Kvartalsrapport 2020-Q1 |
| 2019-11-22 | - | X-dag ordinarie utdelning DMYD B 0.00 SEK |
| 2019-11-21 | - | Årsstämma |
| 2019-10-02 | - | Bokslutskommuniké 2019 |
| 2019-06-26 | - | Kvartalsrapport 2019-Q3 |
| 2019-03-27 | - | Kvartalsrapport 2019-Q2 |
| 2019-01-23 | - | Kvartalsrapport 2019-Q1 |
| 2018-11-16 | - | X-dag ordinarie utdelning DMYD B 0.00 SEK |
| 2018-11-15 | - | Årsstämma |
| 2018-10-03 | - | Bokslutskommuniké 2018 |
| 2018-06-27 | - | Kvartalsrapport 2018-Q3 |
| 2018-03-28 | - | Kvartalsrapport 2018-Q2 |
| 2018-01-24 | - | Kvartalsrapport 2018-Q1 |
| 2017-11-30 | - | Årsstämma |
| 2017-10-31 | - | X-dag ordinarie utdelning DMYD B 0.00 SEK |
| 2017-10-11 | - | Bokslutskommuniké 2017 |
| 2017-06-28 | - | Kvartalsrapport 2017-Q3 |
| 2017-04-05 | - | Kvartalsrapport 2017-Q2 |
| 2017-02-22 | - | Kapitalmarknadsdag 2017 |
| 2017-01-25 | - | Kvartalsrapport 2017-Q1 |
| 2016-11-25 | - | X-dag ordinarie utdelning DMYD B 0.00 SEK |
| 2016-11-24 | - | Årsstämma |
| 2016-10-12 | - | Bokslutskommuniké 2016 |
| 2016-06-29 | - | Kvartalsrapport 2016-Q3 |
| 2016-04-06 | - | Kvartalsrapport 2016-Q2 |
| 2016-01-20 | - | Kvartalsrapport 2016-Q1 |
| 2015-11-27 | - | X-dag ordinarie utdelning DMYD B 0.00 SEK |
| 2015-11-26 | - | Årsstämma |
| 2015-10-14 | - | Bokslutskommuniké 2015 |
| 2015-07-01 | - | Kvartalsrapport 2015-Q3 |
| 2015-04-01 | - | Kvartalsrapport 2015-Q2 |
| 2015-01-21 | - | Kvartalsrapport 2015-Q1 |
| 2014-11-28 | - | X-dag ordinarie utdelning DMYD B 0.00 SEK |
| 2014-11-27 | - | Årsstämma |
| 2014-10-15 | - | Bokslutskommuniké 2014 |
| 2014-07-02 | - | Kvartalsrapport 2014-Q3 |
| 2014-04-09 | - | Kvartalsrapport 2014-Q2 |
| 2014-01-22 | - | Kvartalsrapport 2014-Q1 |
| 2013-11-25 | - | X-dag ordinarie utdelning DMYD B 0.00 SEK |
| 2013-11-22 | - | Årsstämma |
| 2013-11-08 | - | Bokslutskommuniké 2013 |
| 2013-07-03 | - | Kvartalsrapport 2013-Q3 |
| 2013-05-21 | - | 15-7 2013 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Diamyd Medical has been given notice that the USPTO has allowed a patent application and is expected to proceed to grant a patent protecting the use of retogatein (GAD65) to treat individuals with type 1 diabetes carrying the HLA DR3-DQ8 genetic marker. The patent is valid until 2038 and is important to the company's global IP portfolio in precision medicine for type 1 diabetes.
Diamyd Medical currently holds granted precision medicine patents, or has been given notice of allowance, for treating and preventing type 1 diabetes in key global markets:
- Treatment and prevention of type 1 diabetes in individuals carrying HLA DR3-DQ2 using retogatein (GAD65) in the US, Europe, Japan, Eurasia, Mexico, Hong Kong, Israel, South Africa and South Korea, with patent protection extending to 2038. Applications for additional countries are currently pending.
- Treatment and prevention of type 1 diabetes in individuals carrying HLA DR4-DQ8 using insulin as an antigen in Europe, Eurasia, Hong Kong and South Korea, with patent protection also lasting until 2038, and is pending in several other territories.
Together, these two genetic markers - HLA DR3-DQ2 and DR4-DQ8 - are present in up to 90% of individuals with type 1 diabetes, underscoring their broad clinical relevance.
About Diamyd Medical
Diamyd Medical is a Swedish biotechnology company focused on precision medicine approaches for type 1 diabetes and biological manufacturing. The company's investigational drug candidate retogatein, based on recombinant GAD65, was evaluated in the Phase 3 DIAGNODE-3 trial in recent-onset type 1 diabetes. The Company has established a facility for manufacturing of biological products in Umeå, Sweden.
Diamyd Medical's B share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company's Certified Adviser.
For further information, please contact:
Anders Essen-Möller, CEO
Phone: +46 705 51 06 79
E-mail: anders.essen-moller@diamyd.com